drugset
drugset / Trial / NCT05076409

A Study in Healthy Men to Test How Fluconazole Influences the Amount of BI 425809 in the Blood

NCT05076409 ↗

Phase 1 Completed 15 enrolled Boehringer Ingelheim
NaSequentialOpen-labelTreatment

Summary

The main objective of this trial is to investigate the effect of fluconazole, under steady state conditions on the pharmacokinetics of BI 425809 (Reference Treatment R: BI 425809 alone; Test Treatment T: BI 425809 given under steady state conditions of fluconazole).

Timeline

Start
2021-10-19
Primary completion
2022-01-10
Completion
2022-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Iclepertin Small molecule 10 mg Oral
Background Fluconazole Small molecule 400 mg Oral

Indications

No indication recorded.